Warning: The NCBI web site requires JavaScript to function. more...
Interleukin-6 and rheumatic diseases.
Lipsky PE.
Arthritis Res Ther. 2006;8 Suppl 2:S4. Epub 2006 Jul 28. Review.
Related citations
Anti-interleukin-6 receptor antibody therapy in rheumatic diseases.
Nakahara H, Nishimoto N.
Endocr Metab Immune Disord Drug Targets. 2006 Dec;6(4):373-81. Review.
Humanized antihuman IL-6 receptor antibody, tocilizumab.
Nishimoto N, Kishimoto T.
Handb Exp Pharmacol. 2008;(181):151-60. Review.
Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family.
Mihara M, Kasutani K, Okazaki M, Nakamura A, Kawai S, Sugimoto M, Matsumoto Y, Ohsugi Y.
Int Immunopharmacol. 2005 Nov;5(12):1731-40.
Recent advances in immunopathophysiology of interleukin-6: an innovative therapeutic drug, tocilizumab (recombinant humanized anti-human interleukin-6 receptor antibody), unveils the mysterious etiology of immune-mediated inflammatory diseases.
Ohsugi Y.
Biol Pharm Bull. 2007 Nov;30(11):2001-6. Review.
Interleukin-6--a key mediator of systemic and local symptoms in rheumatoid arthritis.
Cronstein BN.
Bull NYU Hosp Jt Dis. 2007;65 Suppl 1:S11-5. Review.
Interleukin-6: from identification of the cytokine to development of targeted treatments.
Assier E, Boissier MC, Dayer JM.
Joint Bone Spine. 2010 Dec;77(6):532-6. Epub 2010 Sep 24. Review.
Anticytokine therapy in autoimmune diseases.
Nishimoto N, Kishimoto T, Yoshizaki K.
Intern Med. 1999 Feb;38(2):178-82. Review.
Interleukin-6 as a key player in systemic inflammation and joint destruction.
Fonseca JE, Santos MJ, Canhão H, Choy E.
Autoimmun Rev. 2009 Jun;8(7):538-42. Epub 2009 Feb 2. Review.
Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling.
Jones SA, Scheller J, Rose-John S.
J Clin Invest. 2011 Sep;121(9):3375-83. doi: 10.1172/JCI57158. Epub 2011 Sep 1. Review.
Targeting interleukin-6 in pediatric rheumatic diseases.
De Benedetti F.
Curr Opin Rheumatol. 2009 Sep;21(5):533-7. Review.
Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer.
Rose-John S, Scheller J, Elson G, Jones SA.
J Leukoc Biol. 2006 Aug;80(2):227-36. Epub 2006 May 17. Review.
Tocilizumab: blockade of interleukin-6 signaling pathway as a therapeutic strategy for inflammatory disorders.
Paul-Pletzer K.
Drugs Today (Barc). 2006 Sep;42(9):559-76. Review.
Inhibition of interleukin-6-transsignaling via gp130-Fc in hemorrhagic shock and sepsis.
Mees ST, Toellner S, Marx K, Faendrich F, Kallen KJ, Schroeder J, Haier J, Kahlke V.
J Surg Res. 2009 Dec;157(2):235-42. Epub 2008 Sep 29.
Influence of humanized anti-IL-6R antibody, tocilizumab on the activity of soluble gp130, natural inhibitor of IL-6 signaling.
Hashizume M, Mihara M.
Rheumatol Int. 2009 Feb;29(4):397-401. Epub 2008 Sep 20.
Clinical value of blocking IL-6 receptor.
Mima T, Nishimoto N.
Curr Opin Rheumatol. 2009 May;21(3):224-30. Review.
Soluble IL-6 receptor induces calcium flux and selectively modulates chemokine expression in human dermal fibroblasts.
Spörri B, Müller KM, Wiesmann U, Bickel M.
Int Immunol. 1999 Jul;11(7):1053-8.
Actual status of antiinterleukin-1 therapies in rheumatic diseases.
Geyer M, Müller-Ladner U.
Curr Opin Rheumatol. 2010 May;22(3):246-51. Review.
The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases.
Kallen KJ.
Biochim Biophys Acta. 2002 Nov 11;1592(3):323-43. Review.
Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses.
Fujimoto M, Serada S, Mihara M, Uchiyama Y, Yoshida H, Koike N, Ohsugi Y, Nishikawa T, Ripley B, Kimura A, Kishimoto T, Naka T.
Arthritis Rheum. 2008 Dec;58(12):3710-9.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on